Atomistry » Fluorine » PDB 8d7z-8dxh » 8dig
Atomistry »
  Fluorine »
    PDB 8d7z-8dxh »
      8dig »

Fluorine in PDB 8dig: Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors

Enzymatic activity of Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors

All present enzymatic activity of Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors:
3.4.22.69;

Protein crystallography data

The structure of Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors, PDB code: 8dig was solved by I.Singh, B.K.Shoichet, with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:

Resolution Low / High (Å) 72.62 / 2.45
Space group P 21 21 21
Cell size a, b, c (Å), α, β, γ (°) 67.779, 102.704, 102.704, 90, 90, 90
R / Rfree (%) 21.4 / 27.1

Fluorine Binding Sites:

The binding sites of Fluorine atom in the Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors (pdb code 8dig). This binding sites where shown within 5.0 Angstroms radius around Fluorine atom.
In total only one binding site of Fluorine was determined in the Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors, PDB code: 8dig:

Fluorine binding site 1 out of 1 in 8dig

Go back to Fluorine Binding Sites List in 8dig
Fluorine binding site 1 out of 1 in the Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors


Mono view


Stereo pair view

A full contact list of Fluorine with other atoms in the F binding site number 1 of Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors within 5.0Å range:
probe atom residue distance (Å) B Occ
A:F401

b:68.9
occ:1.00
 F01 A:U26401 0.0 68.9 1.0
C02 A:U26401 1.4 65.5 1.0
C03 A:U26401 2.4 67.2 1.0
C25 A:U26401 2.4 68.7 1.0
CA A:ASP187 2.9 37.7 1.0
C A:ASP187 3.0 47.5 1.0
N A:ARG188 3.2 46.5 1.0
CB A:ASP187 3.2 45.5 1.0
O A:ASP187 3.5 48.6 1.0
C04 A:U26401 3.6 67.4 1.0
C24 A:U26401 3.6 68.5 1.0
CE A:MET49 3.8 86.7 1.0
C05 A:U26401 4.1 67.1 1.0
SD A:MET165 4.2 65.1 1.0
CA A:ARG188 4.3 47.7 1.0
N A:ASP187 4.3 43.0 1.0
CG A:HIS41 4.3 48.3 1.0
ND1 A:HIS41 4.3 45.5 1.0
O A:VAL186 4.4 45.2 1.0
C A:ARG188 4.5 51.7 1.0
CB A:HIS41 4.5 44.8 1.0
CB A:MET165 4.6 47.9 1.0
CG A:ASP187 4.7 46.1 1.0
O A:ARG188 4.7 55.3 1.0
CD2 A:HIS41 4.7 46.7 1.0
CE1 A:HIS41 4.7 44.2 1.0
CG A:MET165 4.8 46.3 1.0
C A:VAL186 4.8 48.1 1.0
OH A:TYR54 4.8 48.2 1.0
O A:HIS164 4.8 41.9 1.0
NE2 A:HIS41 5.0 48.1 1.0

Reference:

E.A.Fink, C.Bardine, S.Gahbauer, I.Singh, K.White, S.Gu, X.Wan, B.Ary, I.Glenn, J.O'connell Iii, H.O.Donnell, P.Fajtova, J.Lyu, S.Vigneron, N.Young, C.Cohort, I.S.Kondratov, A.O.Donoghue, Y.Moroz, J.Taunton, A.Renslo, J.J.Irwin, A.G.Sastre, B.K.Shoichet, C.S.Craik. Virtual Screening For Novel Sars-Cov-2 Main Protease Non-Covalent and Covalent Inhibitors To Be Published.
Page generated: Wed Jul 16 03:26:45 2025

Last articles

Fe in 9IMN
Fe in 9IL4
Fe in 9IKI
Fe in 9IKH
Fe in 9IAB
Fe in 9IKG
Fe in 9IIG
Fe in 9IAC
Fe in 9IKF
Fe in 9IIU
© Copyright 2008-2020 by atomistry.com
Home   |    Site Map   |    Copyright   |    Contact us   |    Privacy